drugset / Trial / NCT07455825

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

NCT07455825

Phase 1 Completed 65 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (PK), safety and tolerability of different oral formulations of AZD5004, and to evaluate the effect of food on these formulations in healthy participants.

Timeline

Start
2026-03-05
Primary completion
2026-06-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5004 Unknown Oral

Indications

No indication recorded.